The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Open accessAbstract
Cyclin-dependent kinases 12 and 13 (CDK12 and 13) play critical roles in the regulation of gene transcription. However, the absence of CDK12 and 13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells. Here we describe the rational design of a first-in-class CDK12 and 13 covalent inhibitor, THZ531. Co-crystallization with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain. THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II. In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super–enhancer–associated transcription factor genes. Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death. Small molecules capable of specifically targeting CDK12 and 13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“THZ53124, a bulky covalent CDK12/13 inhibitor predicted to clash with DDB1 (Extended Data Fig. 6d–f), locks the CDK12 C-terminal extension in a conformation incompatible with DDB1 recruitment (Extended Data Fig. 6d).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [24]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistently, THZ531 further decreased the TR-FRET signal and diminished cycK ubiquitination in vitro below DMSO control levels (Fig. 3d, Extended Data Fig. 6c, f)24.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“THZ531, a CDK12-CDK13 covalent inhibitor, binds with CDK12-cyclin K via a cysteine residue that is located outside the kinase domain [97].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [97]
In the citing paper
“Furthermore, THZ531 induced cell death and apoptosis in Ewing sarcoma cancer cell lines.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [97]
In the citing paper
“Consistent with this notion, HQ461-mediated depletion of Cyclin K phenotypically mimics dual inhibition of CDK12 and CDK13 by the CDK12/13-selective inhibitor THZ531 to trigger cell death (Zhang et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Zhang et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,713
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citationSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationTranscriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,543
Self-citationControlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130
Rottenberg, S., Jaspers, J. E., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 975
RefSeq: an update on mammalian reference sequences
Pruitt, K. D., Brown, G., Hiatt, S. M., Thibaud‐Nissen, F., Astashyn, A., Ermolaeva, O. D., Farrell, C. M., Hart, J. A., Landrum, M., McGarvey, K. M., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1114 · Cited by 936
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N. P., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B. M., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 865
Self-citationAn oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., et al. (2014) · Science · doi:10.1126/science.1259037 · Cited by 801
Self-citationProgression through the RNA Polymerase II CTD Cycle
Buratowski, S. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.019 · Cited by 777
Young, R. A. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.003353 · Cited by 729
Self-citationCDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N. P., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C. M., Altabef, A. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Self-citationRevisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616
Self-citationDefining mechanisms that regulate RNA polymerase II transcription in vivo
Fuda, N. J., Ardehali, M. B., & Lis, J. T. (2009) · Nature · doi:10.1038/nature08449 · Cited by 576
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
Ahn, S., Kim, M., & Buratowski, S. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00492-1 · Cited by 517
Zhang, Z., & Marshall, A. G. (1998) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(97)00284-5 · Cited by 511
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N. P., Abraham, B. J., Carretero, J., Al‐Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 446
Self-citationCho, E., Kobor, M. S., Kim, M. K., Greenblatt, J., & Buratowski, S. (2001) · Genes & Development · doi:10.1101/gad.935901 · Cited by 428
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Preprint
Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010) · Genes & Development · doi:10.1101/gad.1968210 · Cited by 404
Self-citationCyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Larochelle, S., Amat, R., Glover-Cutter, K. M., Sansó, M., Zhang, C., Allen, J. J., Shokat, K. M., Bentley, D. L., & Fisher, R. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2399 · Cited by 398
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Iñesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 361
Self-citationIn Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E. S., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 358
Self-citationSanda, T., Lawton, L. N., Barrasa, M. I., Fan, Z. P., Kohlhammer, H., Gutiérrez, A., Ma, W., Tatarek, J., Ahn, Y., Kelliher, M. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.007 · Cited by 343
Self-citationSite‐specific recombination of the tal‐1 gene is a common occurrence in human T cell leukemia.
Brown, J. L., Cheng, J. T., Chen, Q., Siciliano, M. J., Crist, W., Buchanan, G., & Baer, R. J. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07535.x · Cited by 342
The multi-tasking P-TEFb complex
Brès, V., Yoh, S. M., & Jones, K. A. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.04.008 · Cited by 241
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 201
Liang, K., Gao, X., Gilmore, J. M., Florens, L. A., Washburn, M. P., Smith, E. R., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 194
Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition
Czudnochowski, N., Bösken, C. A., & Geyer, M. (2012) · Nature Communications · doi:10.1038/ncomms1846 · Cited by 191
Self-citationThe structure and substrate specificity of human Cdk12/Cyclin K
Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014) · Nature Communications · doi:10.1038/ncomms4505 · Cited by 191
Self-citationDavidson, L., Muniz, L., & West, S. (2014) · Genes & Development · doi:10.1101/gad.231274.113 · Cited by 183
Structural and functional analysis of the Cdk13/Cyclin K complex
Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.025 · Cited by 157
Self-citationThe carboxy terminal domain of RNA polymerase II and alternative splicing
Muñoz, M. J., de la Mata, M., & Kornblihtt, A. R. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.03.010 · Cited by 151
Ekumi, K. M., Paculová, H., Lenasi, T., Pospíchalová, V., Bösken, C. A., Rybaříková, J., Bryja, V., Geyer, M., Blažek, D., & Barborič, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 145
Self-citationChen, H.-H., Wang, Y.-C., & Fann, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2736-2745.2006 · Cited by 144
The Crystal Structure of Human CDK7 and Its Protein Recognition Properties
Lolli, G., Lowe, E. D., Brown, N. R., & Johnson, L. N. (2004) · Structure · doi:10.1016/j.str.2004.08.013 · Cited by 142
Cheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
RNA Polymerase II transcription elongation and Pol II CTD Ser2 phosphorylation
Bowman, E. A., & Kelly, W. G. (2014) · Nucleus · doi:10.4161/nucl.29347 · Cited by 116
Ficarro, S. B., Zhang, Y., Lu, Y., Moghimi, A. R., Askenazi, M., Hyatt, E., Smith, E. D., Boyer, L. F., Schlaeger, T. M., Luckey, C. J., et al. (2009) · Analytical Chemistry · doi:10.1021/ac802720e · Cited by 108
Self-citationCDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing
Chen, H.-H., Wong, Y., Genevière, A., & Fann, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.049 · Cited by 83
Cyclin-Dependent Kinase 12 Increases 3′ End Processing of Growth Factor-Induced c-FOS Transcripts
Eifler, T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jäger, S., Johnson, J. R., Luo, Z., Krogan, N. J., & Peterlin, B. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01157-14 · Cited by 63
Sansó, M., & Fisher, R. P. (2013) · Transcription · doi:10.4161/trns.25146 · Cited by 62
mzAPI: a new strategy for efficiently sharing mass spectrometry data
Askenazi, M., Parikh, J. R., & Marto, J. A. (2009) · Nature Methods · doi:10.1038/nmeth0409-240 · Cited by 62
Self-citationBartkowiak, B., & Greenleaf, A. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612226 · Cited by 54
Self-citationEngineering an analog-sensitive CDK12 cell line using CRISPR/Cas
Bartkowiak, B., Yan, C. M., & Greenleaf, A. L. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.010 · Cited by 46
Self-citationYeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction
Bennett, C. B., Westmoreland, T. J., Verrier, C. S., Blanchette, C., Winsor, T. S., Phatnani, H. P., Mishina, Y. V., Hüper, G., Selim, A. L., Madison, E. R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001448 · Cited by 33
Self-citationA DNA Damage Response System Associated with the phosphoCTD of Elongating RNA Polymerase II
Winsor, T. S., Bartkowiak, B., Bennett, C. B., & Greenleaf, A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060909 · Cited by 23
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,229
Self-citationKinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Self-citationPharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552
Self-citationThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
Metadata
- Authors
- Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., Manz, T., Hao, M., Bartkowiak, B., Greenleaf, A. L., Marto, J. A., Geyer, M., Bullock, A. N., Young, R. A., & Gray, N. S.
- Affiliations
- Harvard University (US)
- University of Oxford (GB)
- Whitehead Institute for Biomedical Research (US)
- University of Bonn (DE)
- Dana-Farber Cancer Institute (US)
- Duke Medical Center (US)
- Corresponding author
- Young, Richard A
- Gray, Nathanael S
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2016-08-29
- Volume
- 12
- Issue
- 10
- Pages
- 876-884
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5033074
- OpenAlex
- W2512442926
- Semantic Scholar
- c8164ef9df7e4d3d418a7b07384190780d6ae6a3
- Cited by
- 374
- References
- 59
- Citations by year
- 2026: 39 · 2025: 35 · 2024: 50 · 2023: 44 · 2022: 40 · 2021: 49 · 2020: 38 · 2019: 27 · 2018: 21 · 2017: 27 · 2016: 4
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- PMC
- Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Dana-Farber/Harvard Cancer Center
- Genome Canada (OGI-055)
- Wellcome Trust (106169/Z/14/Z, 092809, 106169, 092809/Z/10/Z, 1097737)
- Diamond Light Source (mx8421, 1097737)
- Ontario Genomics
- Hope Funds for Cancer Research
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Ontario Genomics Institute (OGI-055, 092809/Z/10/Z)
- Ontario Ministry of Economic Development and Innovation (092809/Z/10/Z)
- Deutsche Forschungsgemeinschaft (GE 976/9-1)
- Ministero dello Sviluppo Economico
- National Institutes of Health (CA109901, CA179483)
- Medical Research Council
- National Human Genome Research Institute (R01HG002668)
- National Cancer Institute (R01CA179483, P01CA109901, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- CDK12, CDK13, covalent inhibitors, cyclin K, RNA polymerase II processivity, super-enhancers, DNA damage response genes, transcription factor expression, apoptosis, kinase inhibitors
- MeSH terms
- Anilides, Cysteine, DNA Damage, Humans, Pyrimidines, CDC2 Protein Kinase, Cell Death, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
